Physician profile
Fahd Mousa
NPI 1588026124
$199,788.92
in general payments reported to CMS, 2019-2025
14 companies · $150K in 2025
The $150K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $19.03 · 2021: $239 · 2022: $470 · 2023: $945 · 2024: $47K · 2025: $150K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Honoraria: $75K · Travel and Lodging: $18K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,874.25 |
| Honoraria | $74,525.00 |
| Travel and Lodging | $17,601.71 |
| Food and Beverage | $11,632.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $86,381.35 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $83,799.66 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $26,668.01 | 2023-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $562.90 | 2021-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $484.67 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $466.87 | 2019-2025 | Cobenfy |
| Alkermes, INC. | $439.53 | 2020-2023 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $239.39 | 2021-2023 | |
| Lundbeck LLC | $189.02 | 2024-2025 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $130.00 | 2023 | Libtayo |
| Astellas Pharma US INC | $115.38 | 2024 | Xtandi |
| Allergan, INC. | $110.99 | 2019 | |
| Ironshore Pharmaceuticals INC. | $107.14 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $94.01 | 2024-2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahd Mousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.